ArticleJournal of thoracic disease2024
The impact of immune markers on thymectomy prognosis in thymoma-myasthenia gravis.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.Journal of neurology · 2025Article
- Comparison of outcomes and postoperative immunotherapy between patients with non-thymomatous and thymomatous myasthenia gravis following thymectomy.Therapeutic advances in neurological disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Research shows that thymoma-associated myasthenia gravis (MG) patients exhibit immunological imbalances, including anomalies in immune indicators. The link between these abnormalities and thymectomy outcomes is not well-understood. This study aims to assess the impact of immunological markers like T helper (Th)17 cells, regulatory T (Treg) cells, CD4 Methods: A retrospective analysis of 163 MG patients undergoing thymectomy between January 2011 and December 2022 at our institution was conducted. We explored the association between preoperative blood immunological markers and prognosis using Kaplan-Meier survival curves and the Cox model. The main goal was to determine if these patients could achieve postoperative sustained remission. Results: Out of 163 patients, 77 reached sustained remission, 79 showed no change or worsening of MG, including recurrences, and 7 died from severe MG over an average of 68.2 months. A significant finding was that reduced complement C3 levels (P<0.001) correlated with a failure to achieve remission. Other immunological markers, including T cell levels and IgG, showed no prognostic significance. Conclusions: Complement C3 level is a crucial predictor for long-term remission in thymoma-associated MG post-thymectomy. Patients with lower C3 levels are more likely to experience MG symptom progression post-surgery compared to those with normal levels, indicating its potential as a key prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.